4.7 Article

Comparative in vitro and in vivo antimalarial activity of the indole alkaloids ellipticine, olivacine, cryptolepine and a synthetic cryptolepine analog

期刊

PHYTOMEDICINE
卷 20, 期 1, 页码 71-76

出版社

ELSEVIER GMBH
DOI: 10.1016/j.phymed.2012.09.008

关键词

Plasmodium falciparum; Plasmodium berghei; Murine macrophages; Antiplasmodial activity; Indole alkaloids

资金

  1. Brazilian Malaria Network [CNPq 555665/2009-7, CNPq 555669/2009-2]
  2. Bionorte CNPq [554317/2010-9]
  3. MCT/INPA/INPA
  4. PRONEX/FINEP [023/2009]
  5. Science and Technology Foundation of Portugal [PTDC/SAU-FAR/114864/2009, PEst-OE/SAU/UI4013/2011]
  6. Fundação para a Ciência e a Tecnologia [PTDC/SAU-FAR/114864/2009] Funding Source: FCT

向作者/读者索取更多资源

Indole alkaloids ellipticine (1), cryptolepine triflate (2a), rationally designed 11-(4-piperidinamino)cryptolepine hydrogen dichloride (2b) and olivacine (3) (an isomer of 1) were evaluated in vitro against Plasmodium falciparum and in vivo inPlasmodium berghei-infected mice. 1-3 inhibited P. falciparum (IC50 <= 1.4 mu M, order of activity: 2b >1 > 2a > 3). In vitro toxicity to murine macrophages was evaluated and revealed selectivity indices (SI) of 10-12 for 2a and SI> 2.8 x 102 for 1, 2b and 3.1 administered orally at 50 mg/kg/day was highly active against P. berghei (in vivo inhibition compared to untreated control (IVI) = 100%, mean survival time (MST)> 40 days, comparable activity to chloroquine control). 1 administered orally and subcutaneously was active at 10 mg/kg/day (IVI = 70-77%; MST= 27-29 days). 3 exhibited high oral activity at >= 50 mg/kg/day (IVI =90-97%, MST= 23-27 days). Cryptolepine (2a) administered orally and subcutaneously exhibited moderate activity at 50 mg/kg/day (IVI =43-63%, MST= 24-25 days). At 50 mg/kg/day, 2b administered subcutaneously was lethal to infected mice (MST= 3 days) and moderately active when administered orally (IVI =45-55%, MST = 25 days). 1 and 3 are promising compounds for development of antimalarials. (C) 2012 Elsevier GmbH. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据